Doxorubicin - Oasmia Pharmaceutical

Drug Profile

Doxorubicin - Oasmia Pharmaceutical

Alternative Names: Doxophos

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oasmia Pharmaceutical
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Endometrial cancer; Ewing's sarcoma; Gastric cancer; Germ cell and embryonal neoplasms; Head and neck cancer; Hodgkin's disease; Leukaemia; Lung cancer; Multiple myeloma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Prostate cancer; Rhabdomyosarcoma; Soft tissue sarcoma; Thyroid cancer; Wilms' tumour
  • Preregistration Cancer

Most Recent Events

  • 16 Aug 2017 Chemical structure information added
  • 08 Aug 2017 Registered for Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Breast cancer, Cancer, Endometrial cancer, Ewing's Sarcoma, Gastric cancer, Germ cell cancer, Head and neck cancer, Hodgkin's disease, Leukaemia, Lung cancer, Multiple myeloma, Neuroblastoma, Non-Hodgkin's lymphoma, Osteosarcoma, Ovarian cancer, Prostate cancer, Rhabdomyosarcoma, Soft tissue sarcoma, Thyroid cancer, Wilms' tumour in Russia (IV)
  • 26 Aug 2016 Oasmia Pharmaceutical plans a phase I trial for Breast cancer (Metastatic disease)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top